Based on the close association of Psf3 with the activity of DNA replication and cancer proliferation, we considered that adjuvant UFT administration would be relatively more advantageous for patients with high expression of Psf3 and that Psf3 could be a biomarker of UFT as adjuvant therapy for stage IA patients. This evidence concerns the gene GINS3 and cancer.